Stock analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.
Separately, Roth Mkm reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Bio-Path in a report on Monday, July 8th.
View Our Latest Stock Report on BPTH
Bio-Path Price Performance
Bio-Path (NASDAQ:BPTH – Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same period last year, the firm posted ($10.60) EPS. On average, sell-side analysts anticipate that Bio-Path will post -6.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is owned by institutional investors and hedge funds.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading
- Five stocks we like better than Bio-Path
- There Are Different Types of Stock To Invest In
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Most active stocks: Dollar volume vs share volume
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- About the Markup Calculator
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.